Psoriasis-cell Mediated Autoimmune Disease: A Review
Abstract
Psoriasis is a widespread chronic inflammatory skin condition that affects about 2% of the population. It was recognized as a unique entity in the early 19th century by Robert Willan. The mechanism of infection is due to the exaggerated proliferation of keratinocytes secondary as a result of the activity of the immune system. Different factors cause psoriasis, which includes genetic factors, age, gender, stress, and Bacterial infection. There are several forms of psoriasis, the most prevalent of which is psoriasis Vulgaris (plaque-like psoriasis), which accounts for 90 percent of all cases. Biological therapy is an effective treatment for psoriasis and other autoimmune diseases comparing with chemotherapy and phototherapy.Keywords:
Biological Therapy, Keratinocytes, Psoriasis, T-CellsReferences
1. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clinical and Experimental Dermatology. 2001;26(4):314-320.
2. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. The Lancet. 2007;370(9583):263-271.
3. Villanova F, Flutter B, Tosi I, Grys K, Sreeneebus H, Perera GK, Chapman A, Smith CH, Di Meglio P, Nestle FO. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. Journal of Investigative Dermatology. 2014 Apr 1;134(4):984-991.
4. Zangeneh FZ, Shooshtary FS. Psoriasis-types, causes and medication. InPsoriasis-Types, Causes and Medication 2013 Apr 17. IntechOpen.
5. Murad AA, Hussien WM. Incidance of Psoriasis in Patients with Different Skin Diseases in Baquba City. Diyala Journal of Medicine. 2017;12(1):25-28.
6. Razzaq MSA, Al-Saadi MAK, Ahmed MM, Naji AT. Assessment of genetic variations associated with susceptibility to psoriasis among Iraqi population. Karbala Journal of Medicine. 2015; 8(1):2049-2055.
7. Abdul-Hussein AA, Hussain FE. Childhood psoriasis a clinical and epidemiological study in Samawa city. Muthanna Medical Journal. 2019;6(2):29-34.
8. Hassoon HJ, Risan FA, Abdul-Muhaimen N. Estimation The concentration of IL-23, and IL-17A in the sera of patients with psoriasis in Baghdad city. Iraqi Journal of Biotechnology. 2014; 13(2): 75-85.
9. WHO. Global report on psoriasis. 2016.
10. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994.
11. Chandra A, Ray A, Senapati S, Chatterjee R. Genetic and epigenetic basis of psoriasis pathogenesis. Molecular Immunology. 2015;64(2):313-323.
12. Nevitt GJ, Hutchinson PE. Psoriasis in The community: prevalence severity and patients' beliefs and attitudes towards the disease. British Journal of Dermatology. 1996;135(4):533-537.
13. Basavaraj KH, Navya MA, & Rashmi R. Stress and quality of life in psoriasis: an update. International Journal of Dermatology. 2011;50(7):783-792.
14. Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. International Journal of Molecular Sciences. 2019;2020(18):4347.
15. Zeng J, Luo S, Huang Y, Lu Q. Critical role of environmental factors in The pathogenesis of psoriasis. The Journal of Dermatology. 2017;44(8):863-872.
16. Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatologic Clinics. 2015;33(1):13-23
17. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annual Review of Immunology. 2014;32:227-255.
18. El-Darouti M, Hay RB. Psoriasis: highlights on pathogenesis, adjuvant therapy and treatment of resistant and problematic cases (part I). J. Egypt. Women. Dermatol. Soc. 2010;7:64-67.
19. Goodman WA, Cooper KD, McCormick TS. Regulation generation: The suppressive functions of human regulatory T cells. Critical ReviewsTM in Immunology. 2012;32(1):65-79.
20. Nestle FO, Kaplan DH, Barker J. Psoriasis. The New England Journal of Medicine. 2009;361(5):496-509.
21. Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmunity Reviews. 2014; 13(4-5):490-495.
22. Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Annals of The Rheumatic Diseases. 2005;64(2): ii18-ii23.
23. Lønnberg AS, Skov L. Co-morbidity in psoriasis: mechanisms and implications for treatment. Expert Review of Clinical Immunology. 2017;13(1):27-34.
24. Caporali R, Pallavicini FB, Filippini M, Gorla R, Marchesoni, A, Favalli EG, Sarzi-Puttini P, Atzeni F, & Montecucco C. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmunity Reviews. 2009;8(3):274-280.
25. Abbasi M, Mousavi MJ, Jamalzehi S, Alimohammadi R, Bezvan MH, Mohammadi H, Aslani S. Strategies toward rheumatoid arthritis therapy; The old and the new.Journal of Cellular Physiology. 2019;234(7):10018-10031.
26. Azevedo VF, Della CL. Adalimumab: A review of the reference product and biosimilars. Biosimilars. 2016;6:44-29.
27. Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Annals of The Rheumatic Diseases. 2014; 73(1):3-5.
28. Doan T, Massarotti E. Rheumatoid arthritis: an overview of new and emerging therapies. The Journal of Clinical Pharmacology. 2005;45(7): 751-762.
29. Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. MeThotrexate: an old new drug in autoimmune disease. Expert Review of Clinical Immunology. 2014;10(11):1519-1530.
30. Walker D, Jacobe H. Phototherapy in the age of biologics. 2011;30(4): 190-198.
31. Juzeniene A, Moan J. Beneficial effects of UV radiation other than via vitamin D production. Dermato-Endocrinology. 2012;4(2):109-117.
Published
Abstract Display: 0 
PDF Downloads: 0 
